Published in Med Decis Making on June 14, 2011
Comparative Effectiveness of FITs With Colonoscopy | NCT03264898
Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut (2013) 2.50
Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making (2011) 1.71
Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med (2012) 1.52
The Your Disease Risk Index for colorectal cancer is an inaccurate risk stratification tool for advanced colorectal neoplasia at screening colonoscopy. Cancer Prev Res (Phila) (2012) 1.48
Colorectal cancer screening--optimizing current strategies and new directions. Nat Rev Clin Oncol (2013) 1.35
Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer (2014) 1.08
Interval Colorectal Cancer After Colonoscopy: Exploring Explanations and Solutions. Am J Gastroenterol (2015) 0.88
Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications. Med Decis Making (2016) 0.85
Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. Clin Gastroenterol Hepatol (2016) 0.83
Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection. Int J Cancer (2014) 0.81
A simulation model of colorectal cancer surveillance and recurrence. BMC Med Inform Decis Mak (2014) 0.79
Optimal colorectal cancer screening in states' low-income, uninsured populations—the case of South Carolina. Health Serv Res (2014) 0.78
Imaging-based screening: understanding the controversies. AJR Am J Roentgenol (2014) 0.78
Advances in Fecal Tests for Colorectal Cancer Screening. Curr Treat Options Gastroenterol (2016) 0.77
Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer. Cell Biosci (2015) 0.77
Using models to make policy: an inflection point? Med Decis Making (2011) 0.77
Role of Urinary Biomarkers in the Diagnosis of Adenoma and Colorectal Cancer: A Systematic Review and Meta-Analysis. J Cancer (2016) 0.75
Cross-model comparisons to improve the value of modeling: the case of colorectal cancer screening. Med Decis Making (2011) 0.75
A cross-cultural perspective on challenges facing comparative cancer survivorship research. J Cancer Epidemiol (2011) 0.75
Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med (1993) 27.80
Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet (1996) 20.53
Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet (1996) 18.89
Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2008) 16.82
Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet (2010) 15.50
Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology (2003) 14.67
The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med (2000) 13.19
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin (2008) 12.90
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology (1997) 9.70
Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst (1999) 8.08
Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med (2008) 6.99
Screening for colorectal cancer: recommendation and rationale. Ann Intern Med (2002) 6.56
Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med (2000) 6.26
Cost-effectiveness of screening for colorectal cancer in the general population. JAMA (2000) 5.88
Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med (2002) 5.76
Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ (2009) 5.69
Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med (2001) 3.49
American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin (2006) 3.46
Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut (1982) 3.23
Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst (2010) 3.05
Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"--SCORE. J Natl Cancer Inst (2002) 3.00
Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med (2001) 2.87
The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer (1982) 2.85
Adenomatous polypi of large intestine: incidence and distribution. Ann Surg (1963) 2.74
INCIDENCE AND DISTRIBUTION OF ADENOMATOUS POLYPS OF THE COLON AND RECTUM BASED ON 1,000 AUTOPSY EXAMINATIONS. Dis Colon Rectum (1964) 2.54
Adenomatous lesions of the large bowel: an autopsy survey. Cancer (1979) 2.41
Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas. A necropsy study in New Zealand. Gut (1992) 2.15
Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer (1985) 2.08
The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res (1999) 1.98
A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care (2000) 1.94
Polyps of the large intestine in Aarhus, Denmark. An autopsy study. Scand J Gastroenterol (1989) 1.79
Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making (2011) 1.71
Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol (2009) 1.69
Polyps of the colon in Barcelona, Spain. An autopsy study. Cancer (1988) 1.57
Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol (2000) 1.43
Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med (2010) 1.24
Screening for colorectal cancer in a high-risk population. Results of a mathematical model. Gastroenterology (1987) 1.17
Cost effectiveness of colorectal cancer screening in the elderly. Ann Intern Med (1991) 1.14
Cost-effectiveness of double-contrast barium enema in screening for colorectal cancer. AJR Am J Roentgenol (1998) 1.03
The pathogenesis of colorectal cancer. Introduction. Major Probl Pathol (1978) 0.90
Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial. J Med Screen (2004) 0.86
Cost effectiveness of HemoQuant versus Hemoccult for colorectal cancer screening. J Gen Intern Med (1988) 0.79
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med (2005) 16.70
Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med (2012) 16.55
Cancer statistics, 2004. CA Cancer J Clin (2004) 15.72
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med (2010) 11.99
Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst (2011) 10.29
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Collaborative care for patients with depression and chronic illnesses. N Engl J Med (2010) 8.92
Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med (2003) 7.73
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med (2008) 6.99
Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst (2002) 6.87
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med (2014) 6.54
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol (2011) 5.72
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology (2006) 4.57
De facto long-term opioid therapy for noncancer pain. Clin J Pain (2008) 3.85
Estimating average annual per cent change in trend analysis. Stat Med (2009) 3.54
Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf (2009) 3.25
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin (2006) 3.21
Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology (2011) 3.08
Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care (2009) 3.06
Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst (2010) 3.05
Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst (2002) 3.04
Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev (2009) 3.04
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation (2006) 2.68
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology (2008) 2.56
Estimating average annual percent change for disease rates without assuming constant change. Biometrics (2006) 2.51
Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut (2013) 2.50
Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) (2008) 2.47
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev (2012) 2.39
Depression and increased mortality in diabetes: unexpected causes of death. Ann Fam Med (2009) 2.37
Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst (2009) 2.35
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann Intern Med (2014) 2.31
Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst (2012) 2.30
Cost-effectiveness of colorectal cancer screening. Epidemiol Rev (2011) 2.24
Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst (2008) 2.23
Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev (2007) 2.21
Does response on the PHQ-9 Depression Questionnaire predict subsequent suicide attempt or suicide death? Psychiatr Serv (2013) 2.20
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
Statin use and the risk of breast and prostate cancer. Epidemiology (2002) 2.15
Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med (2013) 2.15
Comparability of segmented line regression models. Biometrics (2004) 2.12
Nurse navigators in early cancer care: a randomized, controlled trial. J Clin Oncol (2013) 2.09
Effect of breast augmentation on the accuracy of mammography and cancer characteristics. JAMA (2004) 2.07
Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ (2012) 2.05
Trends in esophageal adenocarcinoma incidence and mortality. Cancer (2012) 2.03
Age-conditional probabilities of developing cancer. Stat Med (2003) 2.03
Testing the effect of computer-assisted detection on interpretive performance in screening mammography. AJR Am J Roentgenol (2006) 1.98
Changing area socioeconomic patterns in U.S. cancer mortality, 1950-1998: Part I--All cancers among men. J Natl Cancer Inst (2002) 1.97
Screening mammography: clinical image quality and the risk of interval breast cancer. AJR Am J Roentgenol (2002) 1.97
Individualizing colonoscopy screening by sex and race. Gastrointest Endosc (2009) 1.96
Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst (2009) 1.89
At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer (2009) 1.88
Functional outcomes of multi-condition collaborative care and successful ageing: results of randomised trial. BMJ (2011) 1.85
Trends in long-term opioid therapy for noncancer pain among persons with a history of depression. Gen Hosp Psychiatry (2009) 1.84
Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst (2008) 1.83
National Polyp Study data: evidence for regression of adenomas. Int J Cancer (2004) 1.83
Incidence of cervical cancer after several negative smear results by age 50: prospective observational study. BMJ (2009) 1.81
Bias associated with self-report of prior screening mammography. Cancer Epidemiol Biomarkers Prev (2009) 1.75
Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population. Risk Anal (2012) 1.74
The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am (2002) 1.73
Colorectal cancer mortality prevented by use and attributable to nonuse of colonoscopy. Gastrointest Endosc (2011) 1.72
Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making (2011) 1.71
SELECTING THE NUMBER OF CHANGE-POINTS IN SEGMENTED LINE REGRESSION. Stat Sin (2009) 1.69
Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am J Gastroenterol (2011) 1.66